Investigation of inflammatory cytokines and new biomarkers in ischemic heart diseases

##plugins.themes.academic_pro.article.sidebar##

Published Mar 10, 2026
https://doi.org/10.62438/tunismed.v104i01.6454
Download
PDF
Vol. 104 No. 01 (2026): Tunis Med Jan 2026

##plugins.themes.academic_pro.article.main##

Imen Bouhlel
Service of Cardiology, Research laboratory (“insuffisancecardiaque” LR12SP09), 4000 , Sousse, Farhat Hached Hospital, Tunisia
Fekher Jaoued
Department of Cardiology, Research laboratory (“insuffisancecardiaque” LR12SP09), 4000 , Sousse, Farhat Hached Hospital, Tunisia
Youssef Ben Youssef
Department of Cardiology, Research laboratory (“insuffisancecardiaque” LR12SP09), 4000 , Sousse, Farhat Hached Hospital, Tunisia
Muayed Hussein Amer
Department of Pharmacology, Research laboratory ( “insuffisancecardiaque” LR12SP09), University of Thi-Qar, College of Medicine, Thi-Qar 6400I , Iraq
Alsoafi Ali Esmail
Department of Pharmacology, Research laboratory ( “insuffisancecardiaque” LR12SP09), University of Thi-Qar, College of Medicine, Thi-Qar 6400I , Iraq
Wassim Saoudi
Department of Cardiology, Research laboratory (“insuffisancecardiaque” LR12SP09), 4000 , Sousse, Farhat Hached Hospital, Tunisia
Hamza Ellini
Department of Cardiology, Research laboratory (“insuffisancecardiaque” LR12SP09), 4000 , Sousse, Farhat Hached Hospital, Tunisia
Samia Ernez Hajri
Department of Cardiology, Research laboratory (“insuffisancecardiaque” LR12SP09), 4000 , Sousse, Farhat Hached Hospital, Tunisia
Abdallah Mahdhaoui
Department of Cardiology, Research laboratory (“insuffisancecardiaque” LR12SP09), 4000 , Sousse, Farhat Hached Hospital, Tunisia

Abstract

Introduction-Aim: Ischemic heart disease is a leading cause of global mortality and morbidity,resulting from reduced blood supply to the heart. Biomarkers are pivotal in diagnosing and under standing the disease. This study explores the utility of new biomarkers(cytokines,PLA2(phospholipase A2),hs-CRP (high-sensitivityC-reactiveprotein),PCT(procalcitonin),H-FABP(Heart-type fattyacid-bindingprotein)) for diagnosing ischemic heart diseases.


Methods : Conducted at Nasiriyah Heart Hospital,Iraq,from October 2021 to October 2022,the study Included 86 stable angina patients,50 acute myocardial infarctions(MI)(myocardial infarction) patients, and healthy controls.Serum levels of biomarkers and inflammatory cytokines(TNF α(tumornecrosisfactoralpha),IL-1β(interleukin-1beta),IL-6(interleukin-6),IL-9 (interleukin-9))were measure dusing ELISA(enzyme-linkedimmunosorbentassay) and immunoassays.


Results: Instable angina,the study showed that the level of troponinI didn’t significantly change in patients with stable angina. However, compared with healthy controls, patients showed a significant increase in serum levels of CK-MB(creatinekinase-MB),myoglobin,hs-CRP,H-


FABP,Lp-PLA2(lipoprotein-associated phospholipaseA2),and PCT.Significantly elevated levels of serum IL-6,IL-1ß, IL-9, andTNF-αwere also recorded in patients with stable angina


compared to healthy controls. In IMI group, the study revealed  that serum troponin I level was insignificantly changed.However,compared with controls, a significant increase in the level of myoglobin,CK-MB,hs-CRP,Lp-PLA2,PCT,andH-FABPwere recorded.Significantly elevated levels of serumTNF-α,IL-9,IL-6,andIL-1β were also noted in the patients in comparison with healthy controls.


 Conclusion : Novel biomarkers suchas H-FABP,PCT, Lp-PLA2,andcytokines are valuable diagnostic tools for ischemic heart disease, along side traditional markers like TroponineI,CK-MB,and myoglobin.Targeting cytokines with monoclonal antibodies could enhance therapeutic strategies.

Keywords:

Biomarkers, Cytokines, Ischemic heart disease, stable angina

##plugins.themes.academic_pro.article.details##

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

References

  1. RothGA,JohnsonC,AbajobirA,Abd-AllahF,AberaSF,AbyuG,etal.Global,Regional,
  2. and National Burdenof Cardiovascular Diseases for 10 Causes,1990to2015.JAmColl Cardiol.2017 Jul 4;70(1):1–25.
  3. ShibaHA,GalalSB,TagElDinKA,MohamedLA.A Case control study on ischemic heart disease and serum zinca tAl-Zahraa university hospital.JRecentAdvMed.2022Jul 26;3(2):108–18.
  4. SeverinoP,D’AmatoA,PucciM,InfusinoF,AdamoF,BirtoloLI,etal.Ischemic Heart Disease Pathophysiology Paradigms Overview:From Plaque Activation to Microvascular Dysfunction. IntJ MolSci.2020Oct30;21(21):8118.
  5. MozaffarianD,BenjaminEJ,GoAS,ArnettDK,BlahaMJ,CushmanM,etal.Heart
  6. disease and stroke statistics--2015update:are por tfrom the American Heart Association. Circulation.2015Jan27;131(4):e29-322.
  7. SavareseG,LundLH.Global PublicHealth Burden of Heart Failure. CardFail Rev.2017 Apr;3(1):7–11.
  8. BulargaA,HungJ,DaghemM,StewartS,TaggartC,WereskiR,etal.Coronary Artery and Cardiac Disease in Patients With Type 2 Myocardial Infarction:A Prospective Cohort Study.Circulation.2022Apr19;145(16):1188–200.
  9. SairamSG,SolaS,BarooahA,JavvajiSK,JaipuriaJ,VenkateshanV,etal.Theroleof Lp-PLA2 and biochemistry parameters as potential biomarkers of coronary artery disease in Asian South-Indians:a case-controlstudy. Cardiovasc DiagnTher.2017Dec;7(6):589–97.
  10. PotterJM,HickmanPE,CullenL.Troponins in myocardial infarction and injury.Aust Prescr.2022Apr;45(2):53–7.
  11. FakanyaWM,TothillIE. Detection of the inflammation biomarkerC-reactive proteinin serum samples:towards an optimal biosensor formula.Biosensors.2014Dec;4(4):340–57.
  12. IbrahimMI,MohamedYM,TaherMA,AbdelrahmanMA.The Utility of Serum
  13. Procalcitonin Levelas an Early Diagnostic Biomarker for COVID in Patients Presenting with ST-Elevation Myocardial Infarction Post Primary Percutaneous Coronary Intervention.EgyptJHosp Med.2023Jan 1;90(1):843–51.
  14. Polonschii C,PotaraM,Iancu M,DavidS, BanciuRM, VasilescuA,etal. Progress in the Optical Sensing of Cardiac Biomarkers.Biosensors.2023 Jun 7;13(6):632.
  15. YeXD, HeY, WangS,WongGT,Irwin MG,XiaZ.Heart-type fatty acid binding protein (H-FABP)as a biomarker for acute myocardial injury and long-termpost-ischemic prognosis.ActaPharmacol Sin.2018Jul;39(7):1155–63.
  16. HayrapetyanH,TranT,Tellez-CorralesE,MadirajuC.Enzyme-Linked Immunosorbent Assay:Types and Applications.Methods MolBiolCliftonNJ. 2023;2612:1–17.
  17. MahadevaraoPremnathS,ZubairM.Electrochemiluminescence Method.In:StatPearls
  18. [Internet].TreasureIsland(FL):StatPearls Publishing; 2024[cited2024Nov22].Available from:http://www.ncbi.nlm.nih.gov/books/NBK594228/
  19. WangC,LiuS,JuH.Electrochemiluminescencenanoemitters for immunoassay of protein biomarkers.BioelectrochemistryAmstNeth.2023Feb;149:108281.
  20. KumariA,MishraP,ChaulyaSK,PrasadGM,NadeemM,KiskuV,etal.Estimation of
  21. Soil Nutrients and Fertilizer Dosage UsingIon-Selective Electrodes for Efficient Soil
  22. Management.CommunSoilSciPlantAnal. 2024;1–22.
  23. McCarthyCP,McEvoyJW, JanuzziJL.Biomarkers instable coronary artery disease. Am HeartJ. 2018 Feb;196:82–96.
  24. MajidiM,EslamiV,GhorbaniP,ForoughiM.Are women more susceptible to ischemic
  25. heart disease compared to men?A literature over view.JGeriatrCardiolJGC.2021Apr 28;18(4):289–96.
  26. DaněkJ,HnátekT,MalýM,TáborskýM,BěláčekJ,ŠkvarilJ,etal.Troponin levels in
  27. patients with stable CAD. CorVasa.2017Jun 1;59(3):e229–34.
  28. WJ,LA,KL,SjM,SE,CRR,etal.Necrotic cardiac myocytesskew macrophage polarization towards a classically activated phenotype.PloSOne[Internet].2023Mar30 [cited2024Nov22];18(3).Availablefrom:https://pubmed.ncbi.nlm.nih.gov/36996254/
  29. MaayahM,Grubman S, AllenS,Ye Z,ParkDY, VemmouE,etal.Clinical Interpretation
  30. of Serum Troponinin the Era of High-SensitivityT esting.Diagn BaselSwitz.2024Feb 26;14(5):503.
  31. DuganiSB,AyalaMelendez AP,RekaR,HydoubYM,McCaffertySN,MuradMH,etal.
  32. Risk factors associated with premature myocardial infarction:a systematic review protocol. BMJ Open.2019Feb11;9(2):e023647.
  33. LiX,ZhangF,ZhouH,HuY,GuoD,FangX,etal.InterplayofTNF-α,solubleTNF
  34. receptors andoxidative stress in coronary chronictotalocclusion of the oldest patients with coronaryheart disease.Cytokine. 2020 Jan;125:154836.
  35. DaubertMA,JeremiasA.The utility of troponin measurement to detect myocardial
  36. infarction:review of the current findings.VascHealthRiskManag.2010Sep7;6:691–9.
  37. VikenesK,MelbergT,FarstadM,NordrehaugJE.ElevatedCK-MB values after routine
  38. angioplasty predicts worselong-termprognosisinlow-riskpatients.ScandCardiovascJ SCJ.2010Apr;44(2):69–75.
  39. WuP,Yu S,WangJ,ZouS, YaoDS,XiaochenY.Globalburden, trends,and inequalities
  40. of ischemic heart disease among young adults from1990to2019:apopulation-basedstudy. FrontCardiovascMed.2023;10:1274663.
  41. MotamedH,MohammadiM,TayebiZ,RafatiNavaeiA.The diagnostic utility of creatine
  42. kinase-MBversustotalcreatinephosphokinaseratio in patients with non-ST elevation
  43. myocardial infarction from unstable angina. SAGE Open Med. 2023;11:20503121221148609.
  44. PopaDM,MacoveiL,MoscaluM,SascăuRA,StătescuC.ThePrognosticValueof
  45. CreatineKinase-MB Dynamics after Primary Angioplasty in ST-Elevation Myocardial Infarctions.DiagnBasel Switz.2023Oct6;13(19):3143.
  46. XuLQ,YangYM,TongH,XuCF.Early Diagnostic Performance of Heart-Type Fatty
  47. Acid Binding Proteinin Suspected Acute Myocardial Infarction: Evidence From a Meta-
  48. Analysis of Contemporary Studies. Heart LungCirc.2018 Apr;27(4):503–12.
  49. AslSK,RahimzadeganM.There cent progress in the early diagnosis of acute myocardial
  50. infarction based on myoglobin biomarker:Nano-aptasensorsapproaches.JPharm Biomed Anal.2022Mar20;211:114624.
  51. LanzaGA,CareriG,CreaF.Mechanisms of coronary artery spasm.Circulation.2011Oct 18;124(16):1774–82.
  52. WangQ,WangY,XuD.Research progress on Th 17 and Tregulatory cells and their cytokines in regulating atherosclerosis.Front Cardiovasc Med.2022;9:929078.
  53. ŞahingözE,GöktaşA,MartlıHF,ErS,TezM,ŞahingözE,etal.Comparison of
  54. pathologies in patients operated for transverse colon tumor with embryogenic and
  55. anatomical insights.JComprSurg.2023 Nov30;1(4):66–70.
  56. SmS,FA,RD,HD.Relationship between high-sensitivityC-reactive protein serum levels
  57. and these verity of coronary artery stenosis in patients with coronary artery disease. ARYA
  58. Atheroscler [Internet]. 2016 Sep [cited 2024 Nov 22];12(5). Available from: https://pubmed.ncbi.nlm.nih.gov/28458698/
  59. AsakuraK,MinamiY,NagataT,KatamineM,KatsuraA,HashimotoT,etal.Impact of
  60. theeicosapentaenoicacidtoarachidonicacidratioon plaque characteristics in statin-treated patients with coronary artery disease .JClinLipidol. 2023;17(1):189–96.
  61. BestLG,ZhangY,LeeET,YehJL,CowanL,PalmieriV,etal.C-reactiveproteinasa
  62. predictor of cardiovascular risk in a population with a high prevalence of diabetes: the StrongHeart Study. Circulation. 2005 Aug30;112(9):1289–95.
  63. YousufO,MohantyBD,MartinSS,JoshiPH,BlahaMJ,NasirK,etal.High-sensitivity
  64. C-reactive protein and cardiovascular disease: are solute belief or anelusive link?JAm Coll Cardiol. 2013Jul 30;62(5):397–408.
  65. DevarajS,KumaresanPR,JialalI.EffectofC-reactive protein on chemokine expression
  66. inhuman aorticendothelial cells. JMol CellCardiol. 2004 Mar;36(3):405–10.
  67. LiuY,ZhangD,YinD.Pathophysiological Effects of Various Interleukinson Primary Cell
  68. TypesinCommonHeart Disease. Int J MolSci.2023 Mar30;24(7):6497.
  69. DingZ,WeiY,PengJ, WangS,ChenG,Sun J. The Potential Role of C-ReactiveProtein
  70. in Metabolic-Dysfunction-Associated Fatty Liver Disease and Aging .Biomedicines. 2023 Oct 5;11(10):2711.
  71. RezarR,JirakP,GschwandtnerM,DerlerR,FelderTK,HaslingerM,etal.Heart-Type
  72. FattyAcid-BindingProtein(H-FABP)and itsRole as a Biomarker in Heart Failure:What
  73. Do We Know So Far?J ClinMed. 2020 Jan 7;9(1):164.
  74. XuC,ZhangT,ZhuB,CaoZ.Diagnostic role of postmortemCK-MBincardiac death:a
  75. systematic review andmeta-analysis.ForensicSciMedPathol.2020Jun;16(2):287–94.
  76. KabekkoduSP,MananjeSR,SayaRP.A Study on the Role of HeartType Fatty Acid
  77. Binding Protein in theDiagnosis of Acute Myocardial Infarction.J ClinDiagn Res JCDR. 2016 Jan;10(1):OC07-10.
  78. MatsumotoS,NakataniD, SakataY,SunaS,ShimizuM,UsamiM,etal.Elevated serum
  79. heart-type fattyacid-binding proteinin the convalescent stage predicts long-term outcome
  80. in patients surviving acute myocardial infarction.CircJOffJJpnCircSoc. 2013;77(4):1026–32.
  81. LL,JT,YS,QX,BS,FX,etal.Lipoprotein-associated phospholipase A2predicts
  82. cardiovascular death in patients on maintenance hemodialysis:a7-year prospectivecohort
  83. study.LipidsHealthDis[Internet].2024Dec1[cited2024Nov22];23(1).Availablefrom:
  84. https://pubmed.ncbi.nlm.nih.gov/38216940/
  85. RacherlaS,AroraR.UtilityofLp-PLA2inlipid-loweringtherapy.AmJTher.2012 Mar;19(2):115–20.
  86. DadaN,KimNW,WolfertRL.Lp-PLA2:an emerging biomarker of coronary heart
  87. disease.Expert RevMol Diagn.2002 Jan;2(1):17–22.
  88. AbbasiA,VahabiP,TabatabaeiSA,ShahrzadS,MostafaviA,NikdoustF.The Potential
  89. Role of Serum Procalcitonin and Coronary Angiographic Findings in Patients With Acute
  90. CoronarySyndromesEvaluatedbytheSYNTAXScore.IranHeartJ.2023Jul1;24(3):77–84.
  91. SchuetzP,DanielsLB,KulkarniP,AnkerSD,MuellerB.Procalcitonin:A new biomarker fo rthe cardiologist.Int JCardiol.2016Nov 15;223:390–7.
  92. ZakiHA,BenslimanS,BashirK,IftikharH,FayedMH,SalemW,etal.Accuracyof
  93. procalcitonin for diagnosing sepsis in adult patients admitted to the emergency department:
  94. asystematicreviewandmeta-analysis.SystRev.2024Jan 22;13(1):37.
  95. KellyD,KhanSQ,DhillonO,QuinnP,StruckJ,SquireIB,etal.Procalcitoninasa
  96. prognostic marker in patients with acute myocardial infarction.BiomarkBiochemIndic
  97. Expo Response Susceptibility Chem. 2010Jun;15(4):325–31.
  98. HashemipourSV,PourhosseiniH,Hosseinsabet A. Correlation between the serum
  99. procalciton in level and the extension and severity of coronary artery disease in patients with
  100. non-ST-segment elevation myocardial infarction.Cardiovasc EndocrinolMetab.2019 Jun;8(2):62–6.
  101. SultanRH,AbdallahM,AliTM,AhmedAE,AssalHH,ElesawyBH,etal.The
  102. Associations between Cytokine Levels, Kidney and Heart Function Biomarkers, and
  103. Expression Levels of Angiotensin-Converting Enzyme-2 and Neuropilin-1inCOVID-19 Patients.Vaccines.2022 Jun29;10(7):1045.
  104. BouzidiN,GamraH.Relationship between serum interleukin-6 levels and severity of
  105. coronary artery disease under going percutaneous coronary intervention.BMC Cardiovasc Disord.2023 Nov 28;23(1):586.
  106. TøllefsenIM,SheteligC,SeljeflotI,EritslandJ,HoffmannP,AndersenGØ.High levels
  107. ofinterleukin-6 are associated with final infarct size and adverse clinical events in patients with STEMI.Open Heart.2021Dec;8(2):e001869.
  108. SuJH,LuoMY,LiangN,GongSX,ChenW,HuangWQ,etal.Interleukin-6:ANovel
  109. Target for Cardio-Cerebrovascular Diseases. Front Pharmacol. 2021;12:745061.
  110. Müller J,GorressenS,Grandoch M, Feldmann K,KretschmerI,Lehr S, etal.Interleukin-
  111. -dependent phenotypic modulation of cardiac fibroblasts after acute myocardial infarction. BasicResCardiol. 2014;109(6):440.
  112. Fernández-RuizI.Early inhibition ofIL-6 signalling after an acute MIimproves myocardial salvage.NatRevCardiol.2021Jul;18(7):460.
  113. Białecka M,DziedziejkoV, SafranowK,KrzystolikA,MarcinowskaZ,ChlubekD, etal.
  114. Could Tumor NecrosisFactor Serve asa Markerfor Cardiovascular Risk Factors and Left
  115. Ventricular Hypertrophy in Patients with Early-Onset Coronary Artery Disease? Diagn BaselSwitz.2024Feb18;14(4):449.
  116. FangC,ChenZ,ZhangJ,PanJ,JinX,YangM,etal.The Value of Serum YKL-40and
  117. TNF-α in the Diagnosis of AcuteST-Segment Elevation Myocardial Infarction.Cardiol ResPract. 2022;2022:4905954.
  118. HinkleyH,CountsDA,VonCanonE,Lacy M.TCellsinAtherosclerosis:KeyPlayersin
  119. the Pathogenesis of VascularDisease.Cells. 2023Aug26;12(17):2152.
  120. MahmoudAH,TahaNM,ZakharyM,TadrosMS.PTENgene&TNF-alphainacute
  121. myocardial infarction.IntJ CardiolHeartVasc.2019Jun;23:100366.
  122. PluijmertNJ,AtsmaDE,QuaxPHA.Post-ischemic Myocardial Inflammatory Response:
  123. A Complex and Dynamic Process Susceptibleto Immunomodulatory Therapies.Front CardiovascMed. 2021;8:647785.
  124. ToldoS,MauroAG,CutterZ,AbbateA.Inflammasome,pyroptosis,andcytokinesin
  125. myocardialischemia-reperfusioninjury.AmJPhysiolHeartCircPhysiol.2018Dec 1;315(6):H1553–68.
  126. MoriyaJ.Critical roles of inflammation in atherosclerosis.JCardiol.2019Jan;73(1):22–7.
  127. RichterJ,BrouwerS,SchroderK,WalkerMJ.Inflamma some activationandIL-1β
  128. signalling in group A Streptococcus disease.CellMicrobiol.2021Sep;23(9):e13373.
  129. RidkerPM,MacFadyenJG,ThurenT,EverettBM,LibbyP,GlynnRJ,etal.Effectof
  130. interleukin-1βinhibition with canakinumabon incident lung cancer in patients with
  131. atherosclerosis: exploratory results from arandomised,double-blind,placebo-controlled
  132. trial.Lancet LondEngl. 2017Oct21;390(10105):1833–42.
  133. CappuzzelloC,DiVitoL, MelchionnaR,MelilloG,Silvestri L,CesareoE,etal.Increase
  134. of plasma IL-9and decrease of plasmaIL-5,IL-7, andIFN-γ in patients with chronic heart failure.J TranslMed.2011 Mar21;9:28.
  135. OrmstadH,AassHCD,Lund-SørensenN,AmthorKF,SandvikL.Serumlevelsof
  136. cytokinesand C-reactive protein in acute ischemic stroke patients,and their relation ship to
  137. stroke lateralization,type,and infarct volume.JNeurol.2011Apr;258(4):677–85.